南京医药2025年中报简析：增收不增利

Financial Performance - Nanjing Pharmaceutical reported a total revenue of 27.967 billion yuan for the first half of 2025, an increase of 2.7% year-on-year [1] - The net profit attributable to shareholders was 291 million yuan, a decrease of 6.44% compared to the previous year [1] - In Q2 2025, total revenue reached 13.721 billion yuan, up 3.32% year-on-year, while net profit dropped by 25.17% to 114 million yuan [1] Profitability Metrics - The gross margin was 5.91%, down 4.08% year-on-year, and the net margin was 1.36%, a decline of 6.99% [1] - The total of selling, administrative, and financial expenses was 1.007 billion yuan, accounting for 3.6% of revenue, a decrease of 5.4% year-on-year [1] - Earnings per share (EPS) decreased by 7.5% to 0.22 yuan, while operating cash flow per share was -3.08 yuan, down 71.41% [1] Asset and Debt Management - Cash and cash equivalents decreased by 6.34% to 2.306 billion yuan, while accounts receivable increased by 16.21% to 16.948 billion yuan [1] - Interest-bearing liabilities decreased by 20.97% to 8.231 billion yuan, indicating improved debt management [1] - The company's return on invested capital (ROIC) was 7.08%, with a historical median of 8.11%, suggesting average capital returns [1][2] Business Model Insights - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying factors [2] - The cash flow situation is concerning, with cash assets only 7.19% of total assets and 18.3% of current liabilities [3] - The accounts receivable to profit ratio reached 2970.15%, indicating potential issues with cash collection [3]